Reid A, Murphy C, Steen H J, McGovern V, Shields M D
Royal Belfast Hospital for Sick Children, UK.
Acta Paediatr. 1996 Apr;85(4):421-4. doi: 10.1111/j.1651-2227.1996.tb14053.x.
The aim of this open study was to observe linear growth in young children with asthma treated with nebulized budesonide. Infants and young children (< 3 years old) with severe uncontrolled asthma were studied. They were treated with nebulized budesonide (1-4 mg day-1) and treated for at least 6 months. Height standard deviation scores (HtSDS) were measured before ("pre-measurements") immediately prior to commencing nebulized budesonide therapy (baseline) and after at least 6 months of therapy ("post-measurements"). The mean HtSDS score at pretreatment was -0.21 and at baseline had fallen further to -0.46. The mean HtSDS increased to -0.17 when the post-measurements were made (p = 0.035) after at least 6 months of nebulized budesonide therapy. Treatment with nebulized budesonide for longer than 6 months in very young children with severe asthma was not associated with reduced linear growth.
这项开放性研究的目的是观察雾化布地奈德治疗的哮喘幼儿的线性生长情况。对患有严重未控制哮喘的婴幼儿（<3岁）进行了研究。他们接受雾化布地奈德治疗（1-4毫克/天），治疗时间至少为6个月。在开始雾化布地奈德治疗前（“预测量”）、紧接开始治疗前（基线）以及治疗至少6个月后（“后测量”）测量身高标准差分数（HtSDS）。治疗前的平均HtSDS分数为-0.21，在基线时进一步降至-0.46。在雾化布地奈德治疗至少6个月后进行“后测量”时，平均HtSDS增加至-0.17（p = 0.035）。在患有严重哮喘的非常年幼的儿童中，雾化布地奈德治疗超过6个月与线性生长减缓无关。
